Login to Your Account



Loxbridge Funding Model Starts With Altermune Investment

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 2, 2011

LONDON – Big pharma may be getting more engaged in early stage deals, but the gulf between the end product of a typical academic research program and the kind of inputs that will fit into the bottom end of pharma's drug development pipeline remains an area that is badly in need of new approaches to funding.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription